Clinical trials: Digestive System Cancer
HCC - Hepatocellular Carcinoma
An Exploratory Clinical Study on Neoadjuvant Treatment of Hepatocellular Carcinoma with QL1706 Combined with Lenvatinib
This is a single-center, single-arm, prospective trial to explore the efficacy and safety of neoadjuvant treatment with Iparomlimab and Tuvonralimab Injection combined with lenvatinib in patients with advanced HCC
- Trial name
- NCT06884982
- Testing
- QL1706 Plus Lenvatinib
- Volunteers
- 30 people
- Sponsor
- Northern Jiangsu People's Hospital
Hepatocellular Carcinoma
A Real-world Study of Camrelizumab Combined With Apatinib Mesylate in Unresectable Hepatocellular Carcinoma
To evaluate the efficacy and safety of camrelizumab combined with apatinib mesylate in the treatment of unresectable hepatocellular carcinoma.
- Trial name
- NCT05409482
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Meng Chao Hepatobiliary Hospital of Fujian Medical University
HBV, Primary Liver Cancer
Single-cell RNA Sequencing Resolves the Regulatory Role of HBV on the Hepatocellular Carcinoma Immune Microenvironment
In summary, with the help of single-cell sequencing technology, this study aims to focus on elucidating the influence of HBV-induced hepatocellular carcinoma cell metabolic changes on microenvironment remodeling.
- Trial name
- NCT05677724
- Testing
- HBV DNA Sequencing
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Fubing Wang
Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
AZD0530 (NSC 735464) in Treating Patients With Previously Treated Metastatic Colon Cancer or Rectal Cancer
This phase II trial is studying how well AZD0530 works in treating patients with previously treated metastatic colon cancer or rectal cancer.
- Conditions
- Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer
- Trial name
- NCT00397878
- Testing
- saracatinib, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- National Cancer Institute (NCI)
Adenocarcinoma of the Gastroesophageal Junction, HER2-positive Breast Cancer
Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery
This phase I trial studies the side effects and best dose of Akt inhibitor MK2206 and lapatinib ditosylate when given together with trastuzumab in treating patients with locally advanced or metastatic human epidermal growth…
- Conditions
- Adenocarcinoma of the Gastroesophageal Junction, HER2-positive Breast Cancer, Male Breast Cancer, Recurrent Breast Cancer
- Trial name
- NCT01705340
- Testing
- Akt inhibitor MK2206, trastuzumab, lapatinib ditosylate
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)
Sedation and Analgesia
Dexmedetomidine Versus Ketamine Versus Midazolam in Endoscopic Procedures
This study aims to assess the safety and efficacy of dexmedetomidine versus ketamine versus midazolam combined with propofol in cancer patients undergoing gastrointestinal endoscopic procedures.
- Trial name
- NCT04597268
- Testing
- Dexmedetomidine, Ketamine, Midazolam
- Where
- Egypt
- Volunteers
- 75 people
- Sponsor
- National Cancer Institute, Egypt
Gastric Cancer
Deep vs Moderate Neuromuscular Blocks on Remifentanil for Laparoscopic Gastrectomy
The primary purpose is to compare the remifentanil requirements in deep vs moderate neuromuscular blocks during the surgical pleth index -guided anesthesia in patients undergoing laparoscopic gastrectomy.
- Trial name
- NCT04205097
- Testing
- Neostigmine + glycopyrate, Sugammadex
- Where
- South Korea
- Volunteers
- 120 people
- Sponsor
- Ajou University School of Medicine
Pancreatic Adenocarcinoma Non-resectable
PEGPH20 Plus Gemcitabine With Radiotherapy in Patients With Localized, Unresectable Pancreatic Cancer
This is a single arm phase II trial assessing the potential activity of combination PEGPH20 plus Gemcitabine with radiotherapy in ten patients with localized, unresectable pancreatic adenocarcinoma.
- Trial name
- HALO-IST (NCT02910882)
- Testing
- PEGylated Recombinant Human Hyaluronidase (PEGPH20), Gemcitabine, Radiation
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Scripps Health
Pancreatic Neoplasms
Randomized, Controlled Trial of Endoscopic Ultrasound-Guided Bilateral Celiac Plexus Neurolysis vs Celiac Ganglia Neurolysis to Control Pain in Inoperable Pancreatic Cancer Patients With Inadequate Pain Control by Pain Killer
Pancreatic cancer related pain can be difficult to control, even with high doses of narcotics, whose adverse effects may further impair quality of life.
- Trial name
- NCT02220062
- Testing
- EUS-CPN, EUS-CGN
- Volunteers
- 166 people
- Sponsor
- Samsung Medical Center
Hepatocellular Carcinoma
Evaluation of Diagnostic Efficiency of PIVKA-II and Other Tumor Markers in HCC
The incidence of Hepatocellular carcinoma (HCC) is increasing worldwide. However, most of HCC cases were at advanced stage when the diagnosis established.Early diagnosis improves the prognosis.The study is intended to evaluate…
- Trial name
- NCT03047603
- Testing
- PIVKA-II
- Where
- China
- Volunteers
- 4,005 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Carcinoma, Hepatocellular, Gastric Adenocarcinoma
A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers
This study is a prospective, open label, multi-centre phase 2 trial which assesses the efficacy and safety of standard dosing compared to extended dosing interval of nivolumab, atezolizumab or pembrolizumab in…
- Conditions
- Carcinoma, Hepatocellular, Gastric Adenocarcinoma, GastroEsophageal Cancer, Oesophageal Cancer
- Trial name
- VALUE-CHECK (NCT06422403)
- Testing
- Extended Dosing Interval - A, Extended Dosing Interval - B, Extended Dosing Interval - C
- Where
- Singapore
- Volunteers
- 360 people
- Sponsor
- National University Hospital, Singapore
NAFLD - Nonalcoholic Fatty Liver Disease, Diabetes
PROtocol of Metabolic and Cryptogenic livEr Disease regisTry for intEgration of Omic Studies
The main aim of the study is to set up an observational cohort with NAFLD (Non-alcoholic fatty liver disease) at different stage of disease (from simple steatosis to cirrhosis and/or HCC-Hepatocellular carcinoma) and for…
- Conditions
- NAFLD - Nonalcoholic Fatty Liver Disease, Diabetes, Obesity, Metabolic Syndrome
- Trial name
- PROMETEO (NCT04371042)
- Where
- Italy
- Volunteers
- 5,000 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Gastrointestinal Cancers, Gastrointestinal Cancer Metastatic
Electronic Patient Reported Outcomes in Patients With Gastrointestinal Cancers
This is a randomized trial of patients with gastrointestinal (GI) cancers treated at University of California, San Francisco (UCSF) who are starting a new line of systemic therapy to evaluate the feasibility of electronic patient…
- Trial name
- NCT05359042
- Testing
- Electronic Patient Reported Outcomes platform, Health Related Quality of Life Surveys
- Sponsor
- University of California, San Francisco
Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction
Assessment of Metabolic & Path Response w/ RCT & ImT Before Surgery in Locally Advanced Esoph and Gastro-esoph Jction CA
ARTemIS-Eso is a phase I-II, three-level, open-label trial with a dose-expansion cohort at recommended schedule in both esophageal cancer histological groups (squamous cell carcinoma and adenocarcinoma) of RCT and ImT…
- Conditions
- Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction, Squamous Cell Carcinoma of the Esophagus
- Trial name
- ARTEMIS-Eso (NCT03307941)
- Testing
- Monalizumab, Oxaliplatin, 5-Fluorouracil
- Where
- Belgium
- Sponsor
- Jules Bordet Institute
Depression, Cancer
Mindfulness-based Intervention for Depressive Symptoms Sent Via Text (MINDSET)
The purpose of this study is to develop and test a new intervention to reduce depressive symptoms in post-treatment cancer participants.
- Conditions
- Depression, Cancer, Stage III Breast Cancer, Stage II Breast Cancer
- Trial name
- NCT06811454
- Testing
- MINDSET, Enhanced Usual Care (EUC)
- Where
- United States
- Volunteers
- 76 people
- Sponsor
- Case Comprehensive Cancer Center
Advanced Solid Malignancies
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
This study will assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of AZD9574 individually and in combination with anti-cancer agents in participants with advanced cancer that…
- Trial name
- CERTIS1 (NCT05417594)
- Testing
- AZD9574, Temozolomide (TMZ), [11C]AZ1419 3391
- Where
- 32 sites in United States, Australia and 5 more
- Volunteers
- 695 people
- Sponsor
- AstraZeneca
Acute Kidney Injury, Cancer Colorectal
Propofol and Sevoflurane Anesthesia in Colorectal Cancer Surgery: Incidence of Acute Kidney Injury
The goal of this observational study is to compare anesthetic modalities (intravenous propofol anesthesia with sevoflurane gas anesthesia) in patients who underwent colorectal cancer resection surgery regarding the outcome of…
- Trial name
- PROSACC (NCT05585866)
- Testing
- Anesthesia Agent
- Where
- Sweden
- Volunteers
- 4,000 people
- Sponsor
- Uppsala University
Rectal Cancer
Treatment of Adenocarcinoma of the Rectum With Transanal Local Excision for Complete Responders
The current standard of care for rectal cancer has diminished local recurrence and enhanced survival. Quality of life, however, remains poor for many patients and the probability of distant recurrence is high.
- Trial name
- NCT03941366
- Testing
- Standard of care chemotherapy with the change for avoidance of extensive surgery
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Henry Ford Health System
Rectal Cancer
Ketogenic Diet Compliance in Patients Undergoing Radiotherapy for Pelvic Cancers
Patients with locally advanced non-metastatic adenocarcinoma of the rectum undergoing chemoradiation therapy will be assigned to 2 groups: the intervention group will be prescribed an individualized ketogenic eating plan to be…
- Trial name
- KOMPARC (NCT05938322)
- Testing
- Ketogenic Diet, Standard Diet
- Where
- Italy
- Volunteers
- 194 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Colorectal Cancer Metastatic
Sorafenib Plus Capecitabine (SorCape) in Previously Treated Metastatic Colorectal Cancer
Combining Sorafenib with standard cytotoxic fluoropyrimidine therapy for advanced colorectal cancer may provide clinical benefit when no other treatment remains.
- Trial name
- SorCape (NCT01471353)
- Testing
- Sorafenib Plus Capecitabine (SorCape)
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- University of Florida
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.